Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk

• Biohit highlighted a new scientific review in Cancers supporting non-invasive blood biomarkers to triage gastric cancer risk.
• Results were already published on Aug. 28, 2026, not scheduled for a future presentation.
• The review backed serum pepsinogen testing with H. pylori assessment to prioritize endoscopy referrals in low-incidence Western markets.
• GastroPanel was discussed as a near-term deployable approach, positioning it as a screening funnel rather than an endoscopy replacement.
• Authors flagged the need for more prospective validation in asymptomatic Western populations, a key factor for broader adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohit Oyj published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.